search
Back to results

Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Losartan (+) amlodipine
Placebo to match losartan/amlodipine tablets
Amlodipine camsylate
Placebo to match amlodipine
Sponsored by
Organon and Co
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Uncontrolled hypertension, High blood pressure, Uncontrolled high blood pressure, Untreated high blood pressure, Untreated hypertension, Essential hypertension

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria

  • Participants with essential hypertension:

    • who are on single drug therapy
    • who are newly diagnosed and not yet taking any drug therapy, or have not had any drug therapy for at least 2 weeks prior to entering study
    • who have blood pressure readings of 90mmHg ≤ MSDBP < 110mmHg and 140mmHg ≤ MSSBP <180mmHg after 2 weeks wash-out for patients on single agent.
  • Randomization (Visit 3)

    • After dosing of amlodipine 5mg for 6 weeks, blood pressure readings are:

      • 90mmHg ≤ MSDBP < 110mmHg and 140mmHg ≤ MSSBP < 180mmHg.

Exclusion criteria

  • Participant with MSDBP ≥ 110mmHg or MSSBP ≥ 180mmHg.
  • Participant currently taking ≥ 2 antihypertensive medications (note: fixed-dose combination medicine should be counted as the number of active ingredients).
  • Participant with known secondary hypertension of any etiology.
  • Participant with malignant hypertension or current evidence of impending or active malignant hypertension, including headache, papilledema, cardiac ischemia, or pulmonary congestion precipitated by elevated blood pressure.
  • Participant with known intolerance, contraindication or hypersensitivity to any component of dihydropyridines, angiotensin II receptor blockers.
  • Participant showing positive in pregnancy test, lactating woman, or woman who intends to get pregnant during the study period.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Losartan/amlodipine Treatment Arm

    Amlodipine Treatment Arm

    Arm Description

    One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks.

    2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks.

    Outcomes

    Primary Outcome Measures

    Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8
    Diastolic blood pressure was assessed at baseline and after 8 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.

    Secondary Outcome Measures

    Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 4
    Diastolic blood pressure was assessed at baseline and after 4 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.
    Change in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8
    Systolic blood pressure was assessed at baseline and after 8 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.
    Change in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4
    Systolic blood pressure was assessed at baseline and after 4 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.
    Percentage of Participants Who Achieve Target Blood Pressure at Week 8
    Participants were evaluated at Week 8 to ascertain if target blood pressure had been obtained. Criteria for meeting target BP were: sitting diastolic BP (sitDBP) <90mmHg or sitting systolic BP (sitSBP) <140mmHg) or sitDBP change more than 10mmHg from baseline or sitSBP change more than 20mmHg from baseline.
    Percentage of Participants Who Achieve Target Blood Pressure at Week 4
    Participants were evaluated at Week 4 to ascertain if target blood pressure had been obtained. Criteria for meeting target BP were: sitting diastolic BP (sitDBP) <90mmHg or sitting systolic BP (sitSBP) <140mmHg) or sitDBP change more than 10mmHg from baseline or sitSBP change more than 20mmHg from baseline.
    Percentage of Participants Who Had Peripheral Edema During the Study
    A pitting assessment of edema on both legs was performed at baseline and throughout the study. Participants were assessed in a seated position with both feet extended and the right ankle in a neutral dorsiflexion position. The index finger was pressed firmly over the bony prominence approximately 3cm proximal to the midpoint of the medial malleolus of the right ankle and will be held for three seconds. Presence of a residual indentation in the area after releasing pressure on the index finger was considered positive for pitting edema.
    Change From Baseline in Ankle Circumference at Week 8
    Each ankle was marked with a semi-permanent marker at approximately 3 cm proximal to the midpoint of the medial malleolus to aid consistency in the performance of the measurements. Ankle circumference was measured in both ankles at baseline and Week 8 using a tension controlled tape to minimize error.

    Full Information

    First Posted
    January 13, 2011
    Last Updated
    February 7, 2022
    Sponsor
    Organon and Co
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01277822
    Brief Title
    Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)
    Official Title
    The 8 Weeks, Multicenter, Randomized, Double-blind, Clinical Study To Evaluate Efficacy Of Treatment With Losartan/Amlodipine 100/5 mg Combination Compared To Amlodipine 10 mg Monotherapy In Hypertensive Patients Who Are Not Appropriately Respond To Amlodipine 5 mg Monotherapy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2022
    Overall Recruitment Status
    Completed
    Study Start Date
    May 30, 2011 (Actual)
    Primary Completion Date
    April 22, 2013 (Actual)
    Study Completion Date
    April 22, 2013 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Organon and Co

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study will determine whether using losartan and amlodipine together will be non-inferior in lowering blood pressure than amlodipine alone.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension
    Keywords
    Hypertension, Uncontrolled hypertension, High blood pressure, Uncontrolled high blood pressure, Untreated high blood pressure, Untreated hypertension, Essential hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    334 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Losartan/amlodipine Treatment Arm
    Arm Type
    Experimental
    Arm Description
    One combination tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks. Participants will also receive 2 tablets of placebo for amlodipine 5mg orally, once daily for 8 weeks.
    Arm Title
    Amlodipine Treatment Arm
    Arm Type
    Active Comparator
    Arm Description
    2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks. Participants will also receive 1 tablet of placebo for combination losartan/amlodipine orally, once daily for 8 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Losartan (+) amlodipine
    Other Intervention Name(s)
    COZAAR XQ™
    Intervention Description
    One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo to match losartan/amlodipine tablets
    Intervention Description
    One tablet containing placebo, orally, once daily, for 8 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Amlodipine camsylate
    Intervention Description
    2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo to match amlodipine
    Intervention Description
    2 tablets containing placebo, orally, once daily, for 8 weeks.
    Primary Outcome Measure Information:
    Title
    Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8
    Description
    Diastolic blood pressure was assessed at baseline and after 8 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.
    Time Frame
    Baseline and Week 8
    Secondary Outcome Measure Information:
    Title
    Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 4
    Description
    Diastolic blood pressure was assessed at baseline and after 4 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.
    Time Frame
    Baseline and Week 4
    Title
    Change in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8
    Description
    Systolic blood pressure was assessed at baseline and after 8 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.
    Time Frame
    Baseline and Week 8
    Title
    Change in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4
    Description
    Systolic blood pressure was assessed at baseline and after 4 weeks of treatment with the participant in a seated position using an auto sphygmomanometer. Three measurements were performed at 2-minute intervals and the average of the 3 values of was recorded.
    Time Frame
    Baseline and Week 4
    Title
    Percentage of Participants Who Achieve Target Blood Pressure at Week 8
    Description
    Participants were evaluated at Week 8 to ascertain if target blood pressure had been obtained. Criteria for meeting target BP were: sitting diastolic BP (sitDBP) <90mmHg or sitting systolic BP (sitSBP) <140mmHg) or sitDBP change more than 10mmHg from baseline or sitSBP change more than 20mmHg from baseline.
    Time Frame
    Week 8
    Title
    Percentage of Participants Who Achieve Target Blood Pressure at Week 4
    Description
    Participants were evaluated at Week 4 to ascertain if target blood pressure had been obtained. Criteria for meeting target BP were: sitting diastolic BP (sitDBP) <90mmHg or sitting systolic BP (sitSBP) <140mmHg) or sitDBP change more than 10mmHg from baseline or sitSBP change more than 20mmHg from baseline.
    Time Frame
    Week 4
    Title
    Percentage of Participants Who Had Peripheral Edema During the Study
    Description
    A pitting assessment of edema on both legs was performed at baseline and throughout the study. Participants were assessed in a seated position with both feet extended and the right ankle in a neutral dorsiflexion position. The index finger was pressed firmly over the bony prominence approximately 3cm proximal to the midpoint of the medial malleolus of the right ankle and will be held for three seconds. Presence of a residual indentation in the area after releasing pressure on the index finger was considered positive for pitting edema.
    Time Frame
    up to 8 weeks
    Title
    Change From Baseline in Ankle Circumference at Week 8
    Description
    Each ankle was marked with a semi-permanent marker at approximately 3 cm proximal to the midpoint of the medial malleolus to aid consistency in the performance of the measurements. Ankle circumference was measured in both ankles at baseline and Week 8 using a tension controlled tape to minimize error.
    Time Frame
    Baseline and Week 8

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion criteria Participants with essential hypertension: who are on single drug therapy who are newly diagnosed and not yet taking any drug therapy, or have not had any drug therapy for at least 2 weeks prior to entering study who have blood pressure readings of 90mmHg ≤ MSDBP < 110mmHg and 140mmHg ≤ MSSBP <180mmHg after 2 weeks wash-out for patients on single agent. Randomization (Visit 3) After dosing of amlodipine 5mg for 6 weeks, blood pressure readings are: 90mmHg ≤ MSDBP < 110mmHg and 140mmHg ≤ MSSBP < 180mmHg. Exclusion criteria Participant with MSDBP ≥ 110mmHg or MSSBP ≥ 180mmHg. Participant currently taking ≥ 2 antihypertensive medications (note: fixed-dose combination medicine should be counted as the number of active ingredients). Participant with known secondary hypertension of any etiology. Participant with malignant hypertension or current evidence of impending or active malignant hypertension, including headache, papilledema, cardiac ischemia, or pulmonary congestion precipitated by elevated blood pressure. Participant with known intolerance, contraindication or hypersensitivity to any component of dihydropyridines, angiotensin II receptor blockers. Participant showing positive in pregnancy test, lactating woman, or woman who intends to get pregnant during the study period.

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
    IPD Sharing URL
    http://engagezone.msd.com/ds_documentation.php
    Available IPD and Supporting Information:
    Available IPD/Information Type
    CSR Synopsis
    Available IPD/Information URL
    http://www.merck.com/clinical-trials/study.html?id=0954F-399&kw=0954F-399&tab=access

    Learn more about this trial

    Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)

    We'll reach out to this number within 24 hrs